CLAIMS

1. Diagnostic device for the determination of buprenorphine in a biological fluid, comprising a porous support divided into a first zone on which anti-buprenorphine antibodies labelled with gold clusters have been adsorbed, a second zone on which buprenorphine has been immobilised, and a third zone on which immunoreactive substances that give a different antigen-antibody reaction, independently of the presence of the drug in the sample to be analysed, are adsorbed.

2. Device as claimed in claim 1, wherein the immobilised buprenorphine is conjugated with an immunogenic protein.

3. Device as claimed in claim 2, wherein the immobilised buprenorphine is conjugated with albumin.

4. Device as claimed in any of the preceding claims, wherein the porous support is constituted by cellulose.

5. Device as claimed in claim 4, in the form of strip of microporous paper.

6. A rack comprising a plurality of devices as claimed in claims 1-5, and optionally other devices for the determination of other drugs of abuse.

7. A rack as claimed in claim 6, wherein the strips are separated from one another in compartments open at each end from which they can be removed, said compartments being formed in a re-usable rack closed by two removable lids.

8. A transparent box constituting the kit, comprising a plurality of the devices claimed in claims 1-5, the rack claimed in claims 6 and 7 and optionally other devices for the determination of other drugs of abuse.

9. A method for the determination of buprenorphine in biological fluids which involves contacting the biological fluid sequentially with anti-buprenorphine antibodies labelled with gold clusters, reversibly adsorbed on a

porous support, and detecting the immunocomplex by competition with buprenorphine immobilised in a reading zone of said porous support.